Adoptive immunotherapy using gene-modifi ed T cells redirected against cancer has proven clinical effi cacy and tremendous potential. However, such individualized therapy is complex and the cellmanufacturing process requires extensive training of personnel as well as a dedicated infrastructure, which restricts these clinical procedures to very few institutions worldwide.
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The clinical success of adoptive T cell transfer therapy is resulting in growing enthusiasm as indicated by the increasing number of clinical trials and the involvement of large pharmaceutical companies. The stimulation reagents commonly used to activate T cells are soluble anti-CD3 ± anti-CD28 antibodies that require accessory cells such as antigen presenting cells (APCs). Resulting T cell expansions are often variable and dependent on the quality of the "feeders" used. Alternatively, large beads (2-5 μm) coated with agonistic anti-CD3/ CD28 antibodies are used successfully. However, cell manufacturing processes using such reagents entail manipulations that are suboptimal to implement cell therapy for large numbers of patients.
Aiming to streamline clinical manufacturing of T cells, we have developed a cGMP compliant stimulatory reagent, TransAct, a colloidal reagent consisting of iron oxide crystals embedded into a biocompatible polysaccharide matrix with a diameter of about 100 nm. Agonistic anti-CD3 and anti-CD28 antibodies are coated onto two separate nanomatrices. This clinical grade TransAct fulfi ls the requirements for automated T cell preparations in that it is soluble and can be removed by washing (ease of use), biodegradable, sterile fi ltered (safety) and suitable for potent T cell activation, genemodifi cation and expansion. We have compared the stimulatory potential of TransAct with known large beads. TransAct was able to efficiently stimulate enriched T cells and resulted in highly polyfunctional T cells which were comparable to those generated with large beads. Additionally, the TransAct reagent was shown to prime naïve T cells more effi ciently.
Finally, this novel cGMP reagent has also been successfully implemented into automated processes for the preparation of genemodifi ed T cells using the CliniMACS Prodigy® platform, making this product highly suitable for future clinical application in large patient groups and commercial-scale manufacturing. While the total number of allogeneic cells required to reliably reconstitute hematopoiesis following hematopoietic stem cell transplantation (HSCT) has been established, we know very little about the actual number or characteristics of true long-term, multipotential autologous HSCs, critical for any gene therapy or cord blood transplantation approach. Integration site (IS) analysis in gene therapy trials using integrating retroviral vectors (RV) and lentiviral vectors (LV), suggest very few transplanted clones contribute, but underestimates clonal diversity due to procedural bias. DNA barcoding via RV tagging has successfully quantitated hematopoietic reconstitution in mice, but relevance to human hematopoiesis is limited and DNA barcoded vector libraries reported to date lack complexity to recapitulate quantitative tracking in clinically-relevant large animal models. Moreover, permanent integration of proviral DNA into the cell genome is not a benign molecular event and can infl uence reconstitution kinetics. We hypothesized that IS analysis and DNA barcoding together would provide more robust HSCT reconstitution data. We developed a high complexity (~1.2 million), DNA barcoded LV library encoding the chemotherapy resistance gene MGMT(P140K) and enhanced green fl uorescent protein (GFP) to measure hematopoietic reconstitution following autologous HSCT in pigtailed macaques. A total of 3.6E+06 autologous CD34+ cells (3 x library complexity) were transduced at a MOI of 20 (10 x 2) and infused into two animals following myeloablative total body irradiation. We observed ~2 and 12% GFP+ peripheral blood white blood cells (PB WBCs) following hematopoietic recovery in these animals, respectively. We performed barcode and IS retrieval from PB WBCs collected early (1 month) after HSCT and observed <0.001% of infused clones contributing to hematopoiesis by DNA barcoding, and ~42% fewer clones via MGS-PCR of the same sample, with similar contributions of the most dominant clones identifi ed by each method. Over 1 year following HSCT, a total of 5,089 (0.4%) and 20,799 (1.7%) infused clones contributed to hematopoiesis in each animal, respectively, with polyclonal contribution patterns. At 1 year post-transplant, we analyzed PB WBC subsets and identifi ed a total of 116 and 2,246 clones respectively contributing to each of three lineages (T, B, and granulocyte), suggesting <0.2% of infused CD34+ cells displayed multi-lineage potential. Adjusting for marking levels we estimate between 5000-20,000 clones gave rise to trilineage hematopoiesis at 1 year post-HSCT. These fi ndings underscore the need to quantitatively assess repopulation kinetics of HSCs under various conditions aimed at increasing gene modifi ed cell engraftment. Here we provide a tool by which to comprehensively analyze effi cacy and safety of approaches such as HSC expansion or MGMT(P140K)-mediated in vivo chemoselection, and a baseline for comparison and evaluation in the clinically-relevant nonhuman primate model.
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A Lentiviral Vector-Based miRNA Decoy Library Enables High-Throughput Identifi cation of Disease-Relevant miRNAs microRNA (miRNA) are a class of RNAs whose function is to control the expression of coding genes. More than 600 human miRNAs have been discovered. A number of miRNAs have been shown to have crucial roles in different physiological processes, including cell division, cholesterol metabolism, and innate immunity, however the complete functions of most miRNAs are not known. We recently described the generation of a library of lentiviral vector-based miRNA decoys, which can be used to stably inhibit each conserved miRNA. Here we set out to establish whether the library could be employed as a pool to rapidly screen for disease relevant miRNAs. Specifi cally, we sought to identify miRNAs that infl uence HIV infection of T cells.
A human T cell line was transduced with the vector library pool (all 600 vectors) at low multiplicity of infection (<1) to achieve a single vector copy per cell. More than 1,000,000 cells were transduced to ensure that each miRNA decoy was highly represented in the cell population. Transduced cells were purifi ed from untransduced cell by fl ow sorting on eGFP, which is encoded in the decoy vector. The cells were then infected with a VSV-pseudotyped HIV. This virus contains all the HIV genes (gag, pol, rev, vif, vpr, vpu, etc.) but cannot mobilize due to a frameshift mutation in the envelope gene. Though the virus cannot mobilize, HIV infected cells eventually die due to mechanisms that are still not well understood.
We passaged triplicates of mock or HIV infected cells for 11 days, and then extracted DNA, and PCR amplifi ed the region of the vector encoding the decoy sites. The PCR amplicons were deep-sequenced and the reads were mapped to the decoy database. After normalization, we compared the frequency of each miRNA decoy between mock and HIV infected T cells. Strikingly, while the frequency of the vast majority of the 600 decoys was similar between the two conditions, there were several decoys that were highly enriched or de-enriched in the HIV infected cultures. Of note, the decoys for miR-92a and miR-92b were signifi cantly enriched in HIV infected cells (P<0.001), whereas the miR-425 decoys were signifi cantly de-enriched in HIV infected cells (P<0.001). Interestingly, examination of miRNA deepsequencing data from T cells indicated miR-92a and miR-425 were amongst the most abundant miRNAs in the cells with expression of 14,252 reads per million (RPM) and 1,490 RPM, respectively. Moreover, high-throughput sensor analysis, using a lentiviral sensor library confi rmed that both miR-92 and miR-425 were highly active in T cells.
Taken together, our results indicate that knockdown of miR-92 makes T cells more resistant to HIV-induced death, whereas knockdown of miR-425 makes T cells more susceptible; providing two new potential therapeutic targets for modulating HIV infection. Future studies will be needed to determine the mechanism. This work provides a source of vectors for miRNA knockdown and demonstrates the ability of our miRNA decoy library to be used in pooled parallel analysis to rapidly identify disease-relevant functions of miRNAs. Hematopoietic stem cells (HSCs) are important gene therapy targets, with the potential to correct a variety of innate and acquired hematologic diseases. Lentiviral vectors (LVs) are ideally suited for long-term gene correction in quiescent HSCs due to their ability to integrate into the genome of non-dividing cells, but their effi ciency of gene delivery to HSCs is limited by cell-intrinsic factors that are poorly understood. We previously showed that a brief ex vivo rapamycin treatment enhances LV-mediated gene delivery to human and mouse HSCs up to four-fold without compromising engraftment in immunodefi cient mouse models. We now report the mechanistic basis of these fi ndings, which sheds light on HSC-LV interactions and could lead to improved treatment protocol for clinical applications. We show that rapamycin-induced autophagy is not responsible for LV transduction enhancement in HSCs, as incoming LVs did not co-localize with LC3B + autophagosomes, specifi c autophagy activation with a peptide reduced transduction efficiency, and autophagy-impaired Beclin +/mouse HSCs responded normally to rapamycin. Instead, mTOR inhibition, either allosteric by rapamycin or direct by Torin 1, promotes enhanced endocytic LV entry into the cytoplasm, without affecting pre-entry steps such as cell-surface receptor binding, or post-entry steps such as reverse transcription or integration. Rapamycin may promote multiple aspects of LV entry, including internalization into endosomes and productive endosomal fusion. Enhanced endocytic entry following mTOR inhibition is restricted to HSCs and early myeloid cells and is not observed in mature myeloid cells. Rapamycin-mediated enhancement is observed with vectors bearing other envelope glycoproteins such as LASV, but not A-MLV, RD114, or foamy virus, suggesting it may specifi cally target pH-dependent endocytosis. Our data show that cytoplasmic entry is a major restriction point in LV gene delivery to HSCs, and can be enhanced by a novel, mTOR-regulated endocytic program. Combinatorial methods that target both entry and post-entry restriction may prove optimal for LV-mediated HSC gene therapy.
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Self-inactivating (SIN) lentiviral vectors (LV) have an excellent therapeutic potential as demonstrated in pre-clinical studies and clinical trials. However, weaker mechanisms of insertional mutagenesis could still pose a signifi cant risk in clinical applications. Indeed, taking advantage of two novel in-vivo genotoxicity assays based on systemic vector injection into newborn tumor-prone Cdkn2a-/-and Cdkn2a+/mice, we observed that SIN Lentiviral-Vectors (LVs) harboring strong (SF, Cdkn2a-/-N=33, Cdkn2a+/-N=17) or moderate (human-PGK, Cdkn2a-/-N=31) enhancer/promoters in internal position caused a
